Zevra Therapeutics, Inc. (ZVRA) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary and Q&A reveal strong financial health, strategic market expansion, and increasing patient coverage. While management was vague on some topics, the overall sentiment is positive, with promising European and U.S. market strategies for MIPLYFFA and celiprolol. The company's solid balance sheet supports strategic execution without new capital, and patient enrollment growth indicates positive momentum.
Key Financial Performance
Net Revenue $26.1 million, driven by $22.4 million in net revenue from MIPLYFFA. This represents strong performance attributed to the launch and commercialization of MIPLYFFA.
Cost of Product Revenue $1.2 million, excluding noncash intangible asset amortization. This reflects the cost associated with product revenue generation.
Operating Expense $20.4 million, a decrease of $6.8 million compared to the same quarter a year ago. The reduction is due to decreased R&D expenses and personnel-related costs.
R&D Expense $3.4 million, a decrease of $7.5 million compared to Q3 2024. The reduction is primarily due to the completion of the KP1077 Phase II trial and reduced third-party costs.
SG&A Expense $16.9 million, an increase of $700,000 compared to Q3 2024. The increase is due to additional investments in commercial, medical, and launch activities.
Net Loss $500,000, a significant improvement from a net loss of $33.2 million in Q3 2024. This improvement is attributed to reduced operating expenses and increased revenue.
Cash, Cash Equivalents, and Investments $230.4 million as of September 30, 2025, an increase of $12.7 million compared to the end of Q2 2025. The increase is due to nonoperating cash received from warrant and option exercises and interest income.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
MIPLYFFA: MIPLYFFA is the first treatment approved in the U.S. for Niemann-Pick disease type C (NPC). It halts disease progression at 12 months and shows rapid onset of effect within 12 weeks. Long-term data indicates safety and effectiveness for over 5 years. In Q3, net revenue from MIPLYFFA was $22.4 million, with 8 new prescription enrollment forms received, totaling 137 since launch.
OLPRUVA: OLPRUVA had one new prescription enrollment form in Q3, with covered lives reaching 81%. However, it has not gained traction in the mature UCD market. Zevra has decided to scale back sales and marketing efforts for OLPRUVA while maintaining market access and product availability.
European Expansion for MIPLYFFA: Zevra filed a Marketing Authorization Application (MAA) for MIPLYFFA in Europe, which has been validated and is under review by the European Medicines Agency. The European market has an estimated 1,100 NPC patients. The company is developing a go-to-market strategy and has enrolled 92 patients in an Expanded Access Program in Europe and the U.K.
Financial Performance: Q3 net revenue was $26.1 million, including $22.4 million from MIPLYFFA. Operating expenses decreased by $6.8 million compared to the same quarter last year. Net loss for Q3 was $500,000, a significant improvement from a $33.2 million loss in Q3 2024. Cash and investments totaled $230.4 million as of September 30, 2025.
Cost Efficiency: Operating expenses decreased due to reduced R&D costs following the completion of the KP1077 Phase II trial and reallocation of resources from OLPRUVA to MIPLYFFA.
Celiprolol Development: Zevra is recruiting for the Phase III DiSCOVER trial for Celiprolol as a treatment for Vascular Ehlers-Danlos Syndrome (VEDS). 44 of 150 patients have been enrolled, with efforts focused on clinic relationships, genetic testing, and educational outreach.
AI-Driven Patient Identification: Zevra has implemented AI-driven models to analyze medical records and claims data to identify undiagnosed or untreated NPC patients, enhancing disease awareness and diagnosis.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Risks: The company faces risks associated with the approval process for MIPLYFFA in Europe, as the Marketing Authorization Application is still under review by the European Medicines Agency. Any delays or rejections could impact the company's expansion plans.
Market Penetration Challenges: Despite efforts, OLPRUVA has not gained significant traction in the mature UCD market, leading to scaled-back sales and marketing efforts. This indicates challenges in penetrating well-established markets.
Supply Chain and Reimbursement Risks: The redesign of Medicare Part D rebates impacted MIPLYFFA's net revenue, introducing variability in gross-to-net estimates. This could affect future revenue predictability.
Clinical Trial Risks: The ongoing Phase III DiSCOVER trial for Celiprolol has enrolled only 44 of the required 150 patients, indicating potential delays in trial completion and subsequent commercialization.
Economic and Financial Risks: The company reported a net loss for Q3 2025, and while cash reserves are sufficient, any unforeseen financial pressures could impact strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
European Market Expansion: Zevra plans to expand into the European market, estimating approximately 1,100 people living with NPC. The Marketing Authorization Application (MAA) has been validated and is under review by the European Medicines Agency. The company is developing a go-to-market strategy for Europe, considering either an independent launch or a strategic collaboration. The Expanded Access Program in Europe and the U.K. has enrolled 92 patients, building product experience and fostering relationships with physicians and clinics.
Patent Term Extension: Zevra has requested a patent term extension with the U.S. Patent and Trademark Office for MIPLYFFA, which could provide coverage beyond the term granted through orphan drug exclusivity.
Celiprolol Development: The company is actively recruiting patients for the Phase III DiSCOVER trial to evaluate Celiprolol as a treatment for Vascular Ehlers-Danlos Syndrome (VEDS). The trial has enrolled 44 of the 150 required patients, with an interim analysis planned after 28 qualifying events. Efforts are focused on expanding genetic testing centers and conducting educational outreach to vascular specialists.
MIPLYFFA U.S. Market Performance: Zevra continues to focus on raising awareness of MIPLYFFA and NPC in the U.S. through disease awareness initiatives, genetic testing resources, and AI-driven models to identify undiagnosed patients. The company has achieved 66% reimbursement coverage and reports strong patient adherence and continued treatment.
Financial Position and Resource Allocation: Zevra has $230.4 million in cash, cash equivalents, and investments as of September 30, 2025. The company plans to reallocate resources from OLPRUVA to MIPLYFFA and patient services, maintaining a disciplined approach to operating investments and capital allocation to support strategic priorities.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:As we think about the last 2 quarters, there have been 15 new start forms. Are any of these patients newly diagnosed through your efforts? How are you thinking about finding additional undiagnosed patients in the next few quarters?
A:The last two quarters saw 15 new start forms, with many being newly diagnosed patients identified through disease awareness campaigns, genetic testing collaborations, and advanced analytics. The company is leveraging medical teams, conferences, publications, and machine learning to identify undiagnosed patients. They have achieved 137 prescription enrollment forms, representing approximately 40% of the diagnosed patient population.
Q:How are you thinking about taking advantage of your robust balance sheet in the near to midterm?
A:The company is focused on executing its strategic plan, including the MIPLYFFA launch in the U.S., potential approval in Europe, and supporting Celiprolol. While they generated some cash this quarter, variability remains due to working capital requirements. They aim to apply discipline in capital allocation and prioritize current opportunities.
Q:Since the majority of patients submitting new enrollment forms are newly diagnosed, how are you reaching the additional 200 identified patients? What percentage of patients are getting refills?
A:The majority of new enrollment forms are from previously diagnosed patients, not newly diagnosed ones. The company continues to target identified patients and work with clinicians. They have achieved 66% coverage for patients, with most receiving refills monthly through reimbursement pathways.
Q:What is the average age or weight of patients currently on therapy? Has this differed compared to patients in the Expanded Access Program?
A:The real-world patient population is split 50-50 between children and adults, similar to the Expanded Access Program. The average weight used for pricing was based on the Expanded Access Program, but specific weight guidance is not provided.
Q:What have been the key drivers for the increase in coverage from 52% to 66% this quarter? How is the patient enrollment form split between centers of excellence and non-centers of excellence?
A:The increase in coverage is attributed to the strength of MIPLYFFA's data showing disease progression halting at 12 months. Enrollment forms are coming from both centers of excellence and community-based physicians, with a growing number of prescribers.
Q:When can we expect the next update on Europe? How will the French EAP convert to paid drug upon approval?
A:The company expects a 120-day update post-validation for the European submission, with more details likely at 150 days. Conversion from the French EAP to paid drug will depend on country-specific reimbursement processes. Currently, there are 92 patients in the global EAP, primarily in Europe.
Q:Do you think the addition of patient enrollment forms per quarter has reached a steady state? What variables might cause a step change in that number?
A:It is too early to call the current rate of patient enrollment forms a steady state. Efforts to find and diagnose new patients, along with positive feedback from clinicians and patients, suggest potential for continued growth.
Q:What are your initial thoughts on European pricing relative to the U.S. or the French EAP? What are your latest thoughts on KP1077 and strategic options?
A:European pricing will depend on the label and market dynamics, with potential for faster penetration due to higher diagnosis rates in Europe. The company remains open to strategic alternatives for KP1077 but cannot comment further.
Q:How are you thinking about additional commercial investments behind MIPLYFFA in the U.S. in 2026?
A:The company plans to continue investing in disease awareness, data generation, and patient identification strategies. They will evaluate and adjust investments based on effectiveness, with no major changes expected in 2026.
Q:What is the rough cost to launch in the EU? Is there anything noteworthy about MIPLYFFA inventory levels between Q2 and Q3?
A:The cost to launch in the EU depends on the approach taken, whether through local distributors, a hybrid model, or direct execution. MIPLYFFA inventory levels have remained consistent, with no significant fluctuations.
Q:What is the number of patients with enrollment forms but not yet receiving reimbursed drug? Has the time from enrollment to reimbursed drug changed?
A:The number of patients in the free goods program is small, and most transition to paid drug. The time from enrollment to reimbursed drug has decreased significantly, with some cases now taking as little as 24 hours.
Q:Should we expect gross-to-net adjustments like the recent Medicare Part D true-up to happen regularly?
A:The recent adjustment was specific to changes in Medicare Part D rebates and is now accounted for. Future gross-to-net changes may occur due to payer mix and other dynamics, but this specific issue is resolved.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on European pricing, the cost of launching in the EU, and strategic options for KP1077. They also did not provide precise numbers for patients in the free goods program or specific weight guidance for patients.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AmplifyAssist
Celiprolol
Corporate Communications
DiSCOVER trial
Niemann
Phase III
President Investor
Relations Corporate
amortization expense
center excellence
change
clinician
community MIPLYFFA
confidence
decline
disease awareness
disease therapy
disorder mutation
effort OLPRUVA
expense decrease
face
interest
network
noncash
opportunity MIPLYFFA
outreach
patent term
patient DiSCOVER
patient MIPLYFFA
patient diagnosis
poster presentation
potential
presentation International
relationship
resource MIPLYFFA
specialist
team
term extension
use
ZVRA Transcript
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call summary lacks substantial information on financial performance, strategic initiatives, and shareholder returns. The absence of these details, combined with the acknowledgment of risks in forward-looking statements, suggests a neutral sentiment. Without explicit positive or negative financial metrics, guidance, or new strategic announcements, the stock price is unlikely to experience significant movement in the short term.
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Positive3-9
The earnings call highlights strong financial health with improved net loss, a solid cash position, and manageable debt. The European market expansion and patent extension efforts indicate growth potential. The Q&A session reveals optimism about new patient growth and strategic collaborations, despite some uncertainties. The positive sentiment is bolstered by successful disease awareness campaigns and partnerships. However, variability in sales and lack of specific guidance on some metrics may temper immediate expectations. Overall, the sentiment leans positive, suggesting a likely stock price increase within the 2% to 8% range.
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-15
IAMGOLD Corporation (IMG:CA) Q3 2025 Earnings Call Transcript
Positive11-5
The earnings call reveals strong financial performance with record high revenue and adjusted EBITDA, which are positive indicators. The Q&A section provides clarity on cost improvements and share buybacks, boosting investor confidence. Although some responses lacked specificity, the overall sentiment is positive due to strategic capital allocation and growth plans. The company's robust financial health and clear strategies for cost reduction and production expansion further support a positive outlook.
ZVRA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
